Skip to main content
Fig. 2 | Pediatric Rheumatology

Fig. 2

From: Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review

Fig. 2

ESR, CRP, WBC, IL-6, and TNF-α levels before and after treatment of tocilizumab in the MKD patient. Arrow A indicates the first administration of tocilizumab (240 mg every three weeks). After treatment of tocilizumab in the MKD patient, ESR and CRP fell to normal; however, IL-6 increased occasionally. The levels of WBC and TNF-α were always in the normal range

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096